9 results on '"Ramoni, V."'
Search Results
2. Neonatal Lupus Syndromes
- Author
-
Brucato, A., primary, Cimaz, R., additional, and Ramoni, V., additional
- Published
- 2016
- Full Text
- View/download PDF
3. Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies
- Author
-
Fredi, M, Lazzaroni, M, Tani, C, Ramoni, V, Gerosa, M, Inverardi, F, Sfriso, P, Caramaschi, P, Andreoli, L, Sinico, R, Motta, M, Lojacono, A, Trespidi, L, Strigini, F, Brucato, A, Caporali, R, Doria, A, Guillevin, L, Meroni, P, Montecucco, C, Mosca, M, Tincani, A, Tincani, A., SINICO, RENATO ALBERTO, BRUCATO, ANTONIO LUCA, Fredi, M, Lazzaroni, M, Tani, C, Ramoni, V, Gerosa, M, Inverardi, F, Sfriso, P, Caramaschi, P, Andreoli, L, Sinico, R, Motta, M, Lojacono, A, Trespidi, L, Strigini, F, Brucato, A, Caporali, R, Doria, A, Guillevin, L, Meroni, P, Montecucco, C, Mosca, M, Tincani, A, Tincani, A., SINICO, RENATO ALBERTO, and BRUCATO, ANTONIO LUCA
- Abstract
Objective: Systemic vasculitis (SV) are uncommon diseases that rarely affect women during their reproductive age; little data, mainly retrospective, is available on this topic. The aim of our study was to evaluate maternal/neonatal outcome and disease course before, during and after pregnancy. Methods: Sixty-five pregnancies in 50 women with SV were followed by a multispecialistic team in 8 institutions between 1995 and 2014. Clinical data on pregnancy, 1. year before and 1. year after delivery was retrospectively collected. The rate of pregnancy complications was compared to that of a General Obstetric Population (GOP) of 3939 women. Results: In 2 patients the diagnosis of SV was done during pregnancy; 59 out of the remaining 63 started when maternal disease was quiescent. We recorded 56 deliveries with 59 live births, 8 miscarriages and 1 fetal death. In SV, preterm, particularly early preterm (<. 34. weeks) deliveries and cesarean sections appeared significantly more frequent than in GOP (11.3% vs 5.0%, p=. 0.049 and 48.2% vs 31.0%, p=. 0.009).Vasculitis-related complications occurred in 23 pregnancies (35.4%), with 5 severe events (7.7%) including 3 cases of transient ischemic attack (TIA). Data about the post-partum period were available for 56 pregnancies: 12 flares (21.4%) occurred, with 1 severe event (1.8%). Conclusion: SV patients can have successful pregnancies (especially during a disease remission phase) despite an increased rate of preterm delivery. Severe flares were limited, but the occurrence of 3 TIA suggests that particular attention should be given to possible thrombotic complications in SV patients during pregnancy and puerperium.
- Published
- 2015
4. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies
- Author
-
Pier Luigi Meroni, Mauro Galeazzi, Maria Sole Chimenti, Marco Matucci-Cerinic, Marta Mosca, Carlo Salvarani, Micaela Fredi, Gian Domenico Sebastiani, Maria Gerosa, Salvatore D'Angelo, Antonio Brucato, Giulia Pazzola, Véronique Ramoni, Alessandra Bortoluzzi, Angela Tincani, Laura Andreoli, Andrea Doria, Maria Chiara Gerardi, Paola Conigliaro, Roberto Perricone, Maria Stefania Cutro, Massimo Patanè, Maurizio Cutolo, Marcello Govoni, Cecilia Beatrice Chighizola, Carlo Alberto Scirè, M. Pendolino, M. Meroni, Roberto Caporali, Guido Valesini, Annamaria Iuliano, Elena Elefante, Silvia Bellando-Randone, Francesca Romana Spinelli, Maddalena Larosa, Melissa Alexandre Fernandes, Carlo Selmi, Maria Grazia Lazzaroni, Andreoli, L, Gerardi, M, Fernandes, M, Bortoluzzi, A, Bellando-Randone, S, Brucato, A, Caporali, R, Chighizola, C, Chimenti, M, Conigliaro, P, Cutolo, M, Cutro, M, D'Angelo, S, Doria, A, Elefante, E, Fredi, M, Galeazzi, M, Gerosa, M, Govoni, M, Iuliano, A, Larosa, M, Lazzaroni, M, Matucci-Cerinic, M, Meroni, M, Meroni, P, Mosca, M, Patane, M, Pazzola, G, Pendolino, M, Perricone, R, Ramoni, V, Salvarani, C, Sebastiani, G, Selmi, C, Spinelli, F, Valesini, G, Scire, C, and Tincani, A
- Subjects
0301 basic medicine ,Vasculitis ,medicine.medical_specialty ,Vasculiti ,Pregnancy, Activity indices, Rheumatoid arthritis, Spondyloarthritis, Systemic lupus erythematosus, Autoimmune diseases, Vasculitis ,Autoimmune diseases ,Immunology ,Disease ,Systemic lupus erythematosu ,NO ,Activity indices ,Pregnancy ,Rheumatoid arthritis ,Spondyloarthritis ,Systemic lupus erythematosus ,Disease activity ,03 medical and health sciences ,0302 clinical medicine ,Rheumatic Diseases ,Autoimmune disease ,medicine ,Immunology and Allergy ,Humans ,Intensive care medicine ,Rheumatoid arthriti ,030203 arthritis & rheumatology ,Fetus ,business.industry ,Activity indice ,Maternal disease ,medicine.disease ,HCC MED ,Clinical Practice ,Pregnancy Complications ,Settore MED/16 - Reumatologia ,030104 developmental biology ,Female ,Spondyloarthriti ,business ,Active inflammation - Abstract
Pregnancy requires a special management in women with inflammatory rheumatic diseases (RDs), with the aim of controlling maternal disease activity and avoiding fetal complications. Despite the heterogeneous course of RDs during pregnancy, their impact on pregnancy largely relates to the extent of active inflammation at the time of conception. Therefore, accurate evaluation of disease activity is crucial for the best management of pregnant patients. Nevertheless, there are limitations in using conventional measures of disease activity in pregnancy, as some items included in these instruments can be biased by symptoms or by physiological changes related to pregnancy and the pregnancy itself may influence laboratory parameters used to assess disease activity. This article aims to summarize the current literature about the available instruments to measure disease activity during pregnancy in RDs. Systemic lupus erythematosus is the only disease with instruments that have been modified to account for several adaptations which might interfere with the attribution of signs or symptoms to disease activity during pregnancy. No modified-pregnancy indices exist for women affected by other RDs, but standard indices have been applied to pregnant patients. The current body of knowledge shows that the physiologic changes that occur during pregnancy need to be either adapted from existing instruments or developed to improve the management of pregnant women with RDs. Standardized instruments to assess disease activity during pregnancy would be helpful not only for clinical practice but also for research purposes. info:eu-repo/semantics/publishedVersion
- Published
- 2019
5. Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11 th International Conference on Reproduction, Pregnancy and Rheumatic Diseases.
- Author
-
Andreoli L, Chighizola CB, Iaccarino L, Botta A, Gerosa M, Ramoni V, Tani C, Bermas B, Brucato A, Buyon J, Cetin I, Chambers CD, Clowse MEB, Costedoat-Chalumeau N, Cutolo M, De Carolis S, Dolhain R, Fazzi EM, Förger F, Giles I, Haase I, Khamashta M, Levy RA, Meroni PL, Mosca M, Nelson-Piercy C, Raio L, Salmon J, Villiger P, Wahren-Herlenius M, Wallenius M, Zanardini C, Shoenfeld Y, and Tincani A
- Subjects
- Male, Child, Pregnancy, Female, Infant, Newborn, Humans, Prospective Studies, Reproductive Health, Placenta, Pregnancy Outcome, Biosimilar Pharmaceuticals, Autoimmune Diseases complications, Autoimmune Diseases therapy, Rheumatic Diseases complications, Rheumatic Diseases drug therapy
- Abstract
Autoimmune rheumatic diseases (ARD) can affect women and men during fertile age, therefore reproductive health is a priority issue in rheumatology. Many topics need to be considered during preconception counselling: fertility, the impact of disease-related factors on pregnancy outcomes, the influence of pregnancy on disease activity, the compatibility of medications with pregnancy and breastfeeding. Risk stratification and individualized treatment approach elaborated by a multidisciplinary team minimize the risk of adverse pregnancy outcomes (APO). Research has been focused on identifying biomarkers that can be predictive of APO. Specifically, preeclampsia and hypertensive disorders of pregnancy tend to develop more frequently in women with ARD. Placental insufficiency can lead to intrauterine growth restriction and small-for-gestational age newborns. Such APO have been shown to be associated with maternal disease activity in different ARD. Therefore, a key message to be addressed to the woman wishing for a pregnancy and to her family is that treatment with compatible drugs is the best way to ensure maternal and fetal wellbeing. An increasing number of medications have entered the management of ARD, but data about their use in pregnancy and lactation are scarce. More information is needed for most biologic drugs and their biosimilars, and for the so-called small molecules, while there is sufficient evidence to recommend the use of TNF inhibitors if needed for keeping maternal disease under control. Other issues related to the reproductive journey have emerged as "unmet needs", such as sexual dysfunction, contraception, medically assisted reproduction techniques, long-term outcome of children, and they will be addressed in this review paper. Collaborative research has been instrumental to reach current knowledge and the future will bring novel insights thanks to pregnancy registries and prospective studies that have been established in several Countries and to their joint efforts in merging data., Competing Interests: Declaration of Competing Interest None declared., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies.
- Author
-
Andreoli L, Gerardi MC, Fernandes M, Bortoluzzi A, Bellando-Randone S, Brucato A, Caporali R, Chighizola CB, Chimenti MS, Conigliaro P, Cutolo M, Cutro MS, D'Angelo S, Doria A, Elefante E, Fredi M, Galeazzi M, Gerosa M, Govoni M, Iuliano A, Larosa M, Lazzaroni MG, Matucci-Cerinic M, Meroni M, Meroni PL, Mosca M, Patanè M, Pazzola G, Pendolino M, Perricone R, Ramoni V, Salvarani C, Sebastiani GD, Selmi C, Spinelli FR, Valesini G, Scirè CA, and Tincani A
- Subjects
- Female, Humans, Pregnancy, Pregnancy Complications diagnosis, Pregnancy Complications pathology, Rheumatic Diseases pathology, Pregnancy Complications physiopathology, Rheumatic Diseases physiopathology
- Abstract
Pregnancy requires a special management in women with inflammatory rheumatic diseases (RDs), with the aim of controlling maternal disease activity and avoiding fetal complications. Despite the heterogeneous course of RDs during pregnancy, their impact on pregnancy largely relates to the extent of active inflammation at the time of conception. Therefore, accurate evaluation of disease activity is crucial for the best management of pregnant patients. Nevertheless, there are limitations in using conventional measures of disease activity in pregnancy, as some items included in these instruments can be biased by symptoms or by physiological changes related to pregnancy and the pregnancy itself may influence laboratory parameters used to assess disease activity. This article aims to summarize the current literature about the available instruments to measure disease activity during pregnancy in RDs. Systemic lupus erythematosus is the only disease with instruments that have been modified to account for several adaptations which might interfere with the attribution of signs or symptoms to disease activity during pregnancy. No modified-pregnancy indices exist for women affected by other RDs, but standard indices have been applied to pregnant patients. The current body of knowledge shows that the physiologic changes that occur during pregnancy need to be either adapted from existing instruments or developed to improve the management of pregnant women with RDs. Standardized instruments to assess disease activity during pregnancy would be helpful not only for clinical practice but also for research purposes., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
7. Should we treat congenital heart block with fluorinated corticosteroids?
- Author
-
Brucato A, Tincani A, Fredi M, Breda S, Ramoni V, Morel N, and Costedoat-Chalumeau N
- Subjects
- Heart Block drug therapy, Humans, Infant, Newborn, Adrenal Cortex Hormones therapeutic use, Heart Block congenital, Steroids, Fluorinated therapeutic use
- Published
- 2017
- Full Text
- View/download PDF
8. Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies.
- Author
-
Fredi M, Lazzaroni MG, Tani C, Ramoni V, Gerosa M, Inverardi F, Sfriso P, Caramaschi P, Andreoli L, Sinico RA, Motta M, Lojacono A, Trespidi L, Strigini F, Brucato A, Caporali R, Doria A, Guillevin L, Meroni PL, Montecucco C, Mosca M, and Tincani A
- Subjects
- Abortion, Spontaneous, Cesarean Section, Female, Fetal Death, Humans, Multicenter Studies as Topic, Pregnancy, Pregnancy Outcome, Pregnancy Complications, Systemic Vasculitis complications
- Abstract
Objective: Systemic vasculitis (SV) are uncommon diseases that rarely affect women during their reproductive age; little data, mainly retrospective, is available on this topic. The aim of our study was to evaluate maternal/neonatal outcome and disease course before, during and after pregnancy., Methods: Sixty-five pregnancies in 50 women with SV were followed by a multispecialistic team in 8 institutions between 1995 and 2014. Clinical data on pregnancy, 1year before and 1year after delivery was retrospectively collected. The rate of pregnancy complications was compared to that of a General Obstetric Population (GOP) of 3939 women., Results: In 2 patients the diagnosis of SV was done during pregnancy; 59 out of the remaining 63 started when maternal disease was quiescent. We recorded 56 deliveries with 59 live births, 8 miscarriages and 1 fetal death. In SV, preterm, particularly early preterm (<34weeks) deliveries and cesarean sections appeared significantly more frequent than in GOP (11.3% vs 5.0%, p=0.049 and 48.2% vs 31.0%, p=0.009). Vasculitis-related complications occurred in 23 pregnancies (35.4%), with 5 severe events (7.7%) including 3 cases of transient ischemic attack (TIA). Data about the post-partum period were available for 56 pregnancies: 12 flares (21.4%) occurred, with 1 severe event (1.8%)., Conclusion: SV patients can have successful pregnancies (especially during a disease remission phase) despite an increased rate of preterm delivery. Severe flares were limited, but the occurrence of 3 TIA suggests that particular attention should be given to possible thrombotic complications in SV patients during pregnancy and puerperium., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome.
- Author
-
Spinillo A, Beneventi F, Epis OM, Montanari L, Mammoliti D, Ramoni V, Di Silverio E, Alpini C, Caporali R, and Montecucco C
- Subjects
- Adult, Case-Control Studies, Cohort Studies, Confidence Intervals, Connective Tissue Diseases complications, Connective Tissue Diseases immunology, Female, Fetal Development, Fetal Growth Retardation diagnostic imaging, Fetal Growth Retardation epidemiology, Humans, Incidence, Infant, Newborn, Odds Ratio, Pregnancy, Pregnancy Complications diagnosis, Pregnancy Trimester, First, Premature Birth immunology, Reference Values, Risk Assessment, Ultrasonography, Connective Tissue Diseases pathology, Fetal Growth Retardation etiology, Infant, Small for Gestational Age, Pregnancy Complications pathology, Pregnancy Outcome
- Abstract
Objective: The purpose of this study was to evaluate pregnancy outcome in a cohort of patients with newly diagnosed undifferentiated connective tissue disease (UCTD)., Study Design: We conducted a nested case-control study that compared 41 patients who had early UCTD that was diagnosed at 11-14 weeks of pregnancy with 82 healthy control subjects., Results: During pregnancy, UCTD progressed to a definite connective tissue disease in 2 of 41 patients (4.9%). Sixteen of the 41 patients (39%) with UCTD tested positive for anti-Ro (SSA) antibodies. Compared with the control subjects, the women with UCTD had higher rates of small for gestational age (SGA; 12/40 vs 11/80; P = .05). The rate of complications of pregnancy (preterm delivery at = 37 weeks of gestation, SGA, preeclampsia, late fetal loss) was 39% (16/41) among cases and 13.4% (11/82) in control subjects (adjusted odds ratio, 3.98; 95% CI, 1.59-9.49)., Conclusion: Pregnant patients with UCTD are at increased risk of SGA and complications of pregnancy.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.